Seer to Feature Proteomic Advancements in Cancer and RNA Therapy Research among other Findings at US HUPO 2025

REDWOOD CITY, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will showcase new findings at the 21st Annual US Human Proteome Organization (HUPO) Conference in Philadelphia, PA, from February 22-26, 2025. As a US HUPO Conference sponsor, Seer will host a seminar highlighting novel advances in scalable deep cellular proteomics using Seer’s Proteograph™ Product Suite. The seminar will feature a case study detailing a groundbreaking new co-delivery therapeutic platform for targeting cancer vulnerabilities with siRNA and mRNA therapeutics. The first-of-its-kind study describes the simultaneous inactivation of tumorigenic drivers using siRNA while activating lost tumor suppressors using mRNA and establishes a new core strategy for treatment of a broad range of cancers. Studying the cellular proteomic changes in response to these therapies yields critical biological insights that can drive further improvements in our ability to treat cancer.

Read more at globenewswire.com